Radiobismuth for Therapy

Martin W. Brechbiel, Ekaterina Dadachova

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations
Original languageEnglish (US)
Title of host publicationBiological Chemistry of Arsenic, Antimony and Bismuth
PublisherJohn Wiley and Sons
Pages311-329
Number of pages19
ISBN (Print)9780470713907
DOIs
StatePublished - Nov 15 2010

Keywords

  • 213Bi and 212Bi, metallic in nature - chelation chemistry or bifunctional chelators for antibody linkage
  • Cancer treatment, and surgery - external beam radiation therapy and chemotherapy
  • Chemo-resistance and radio resistance - acquired by tumors, in conventional therapies
  • Landmark clinical trial, Memorial Sloan-Kettering Cancer Center - 213Bi-labeled humanized anti-CD33 monoclonal antibody
  • Monoclonal antibodies (mAbs) - viable strategy for therapeutic delivery
  • Radiobismuth for therapy
  • Radioimmunotherapy of experimental fungal, bacterial and viral infections - and 213bi-labeled antibodies
  • Targeted a-therapy versus targeted b-therapy
  • Targeted radiation therapy - stable sequestration of radionuclide in vivo, delivery of radiation to tumors
  • Targeting vectors, Murine mAbs - against tumor associated antigens (TAA), and multitudes of preclinical studies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Brechbiel, M. W., & Dadachova, E. (2010). Radiobismuth for Therapy. In Biological Chemistry of Arsenic, Antimony and Bismuth (pp. 311-329). John Wiley and Sons. https://doi.org/10.1002/9780470975503.ch13